InSphero, the world's leading provider of 3D cell culture technologies and organ-on-chip systems for drug discovery, has announced its collaboration with the global bio-resource center ATCC. According to a statement from InSphero, which is based in Schlieren in the canton of Zurich, one of the main aims of the collaboration is to provide science and research with unprecedented access to test-ready 3D tumor microtissues. “This is made possible by synergistically coupling ATCC's authenticated cells with InSphero's innovative, industry-leading 3D cell-based assay platforms,” explains the statement.
The partnership will also provide a comprehensive and diverse portfolio of tumor models that will give researchers access to enriched data sets. This should improve decision-making in the discovery and development of drugs. According to InSphero, ATCC offers an “unmatched combination of biological reference materials and data”. Based in Manassas, Virginia, the company is a leading developer and supplier of authenticated cell lines, microorganisms and associated data for academia, industry and government.
“Through this partnership with ATCC, we are fulfilling a long-standing ambition to open new avenues for advancing cancer research at a global scale,” commented Dr. Jan Lichtenberg, CEO of InSphero. “By supplying assay-ready 3D tumor microtissues based on ATCC cells, we're not only significantly accelerating research timelines but also setting a new gold standard for uniformity and reproducibility in the research community.”